Roth Capital affirms Cytokinetics (Nasdaq: CYTK) with a Buy rating and $18 price target after the company and Amgen (Nasdaq ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE